IVA - Inventiva S.A.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Inventiva S.A.

50 rue de Dijon
Daix 21121
33 3 80 44 75 00

Full Time Employees109

Key Executives

NameTitlePayExercisedYear Born
Mr. Frederic CrenCo-Founder, CEO & Chairman541.24kN/A1966
Dr. Pierre Broqua Ph.D.Co-Founder, Chief Scientific Officer, Deputy CEO & Director405.96kN/A1962
Mr. Jean VolatierChief Financial OfficerN/AN/A1965
Mr. Eric Duranson L.L.M.Gen. CounselN/AN/A1974
Ms. Nathalie HarroyHead of HRN/AN/A1967
Dr. Irena KonstantinovaHead of Biology & PharmacologyN/AN/AN/A
Dr. Michael CooremanChief Medical OfficerN/AN/A1958
Mr. Jean-Paul Dutertre M.D.Head of PharmacovigilanceN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Corporate Governance

Inventiva S.A.’s ISS Governance QualityScore as of May 1, 2023 is 7. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 9; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.